Drug intelligence / Profile preview

mixed amphetamine salts (Takeda, 043683)

Development stage
Unknown
Lead developer
Takeda
Modality
Small Molecules
Administration
Oral
01

Overview

Mixed amphetamine salts (MAS) is a central nervous system stimulant medication composed of a specific 3:1 ratio of dextroamphetamine and levoamphetamine salts. The standard formulation includes four salts: amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate. It functions primarily as a releasing agent and reuptake inhibitor of the monoamine neurotransmitters dopamine and norepinephrine. By targeting the dopamine transporter (DAT) and norepinephrine transporter (NET), as well as acting as an agonist at the trace amine-associated receptor 1 (TAAR1), it increases synaptic concentrations of these neurotransmitters, thereby modulating reward circuitry and executive function. While widely approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy, it has been investigated by institutions such as the New York State Psychiatric Institute as a potential pharmacotherapy for cocaine dependence, particularly in patients with comorbid ADHD, to help reduce drug-seeking behavior and improve treatment retention.

Brand names
Adderall XRAdderallMydayisAdzenys XR-ODTDyanavel XR
Other names
MASMAS-ERmixed salts of a single-entity amphetamine productamphetamine mixed salts
02

Targets

DAT (Dopamine plasma membrane transport protein)MAOA (Monoamine oxidase A)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)TAAR1 (Trace amine-associated receptor 1)VMAT2 (Vesicular monoamine transporter 2)

Beyond the preview

Go deeper on mixed amphetamine salts (Takeda, 043683).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mixed amphetamine salts (Takeda, 043683).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call